Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
doi:10.1200/JCO.2026.44.16_suppl.11000 Shah Z, Hundal J, Afridi SS, et al
Image Credit: grinny / Shuttertock In a recent study published in The Lancet , a group of researchers evaluated the efficacy, safety, and tolerability of oral non-peptide small-molecule elecoglipron for weight management in adults with obesity or overweight and at least one weight-related health condition without diabetes
Some individuals might transition to a lower maintenance dose after reaching their goals, while others continue indefinitely
These changes interact with sleep in important ways that deserve attention for optimal results
GLP-1 RAs, such as semaglutide (2.4 mg weekly), have produced 14.9% mean weight loss in the STEP 1 trial [18]
